Selecta Biosciences

Selecta Biosciences, Inc. is an American biotechnology company based in Watertown, Massachusetts. It trades on the NASDAQ under the ticker name SELB.¹⁾

Selecta Biosciences was founded in 2008 by Omid Farokhzad, after its incorporation in 2007.^{2) 3)} The company was founded to develop immunomodulatory nanoparticles for the treatment and prevention of human diseases. Early investors in the then-private startup included Polaris Partners and Flagship Pioneering, the latter of which would soon also launch Moderna.^{4) 5)} They were joined in February 2009 by additional investments from NanoDimension and Professor Timothy Springer (a founding investor in Moderna).⁶⁾

In December 2021, Selecta invested in a Series B funding round for Cyrus Biotechnology.⁷⁾

The company has had license and collaboration agreements with:^{8) 9)}

• Asklepios BioPharmaceutical (AskBio)
• Gingko Bioworks
• IGAN Biosciences
• Massachusetts Institute of Technology (MIT)
• Sarepta Therapeutics
• Shenyang Sunshine Pharmaceutical Co.
• Spark Therapeutics
• Swedish Orphan Biovitrum (Sobi)
• Takeda

Companies that have invested in/provided funding for Selecta include:^{13) 14) 15)}

• Artal Group
• BlackRock
• Boxer Capital
• EcoR1 Capital
• Eminent Venture Capital
• Endurant Capital Management
• Flagship Pioneering
• I2BF Global Ventures
• JPMorgan Chase
• Leukon Investments
• Mangrove Partners
• Millennium Management
• NanoDimension
• Osage University Partners (OUP)
• Oxford Finance
• Polaris Partners
• Sanofi Ventures
• Silicon Valley Bank
• Sphera Funds Management
• Vanguard

• Crunchbase
• LinkedIn
• Twitter